Binfeng Lu, Ph.D., is a Member of the Center for Discovery and Innovation and Georgetown Lombardi Comprehensive Cancer Center.
Dr. Lu’s research area includes tumor immunology and cancer immunotherapy. His lab investigates ways to harness T cell-mediated anti-tumor immune responses to treat cancer. His team has performed molecular characterization of tumor-associated Treg cells with the discovery of TIM3+ Treg cells in the tumor immune suppressive microenvironment, established key transcription factors, such as Tbet and Eomes, that regulate tumor-specific memory stem T cells, and ushered in novel cytokine-based cancer immunotherapy based on tissue alarmin cytokines, such as IL-33 and IL-36.
At CDI, the Lu lab studies fundamental molecular mechanisms underpinning anti-tumor immune cellular networks, leveraging data science, cutting-edge immunological techniques, clinically relevant mouse cancer models, and a rich collection of human cancer specimens. The lab’s combined basic and translational research approach will catalyze innovative NextGen immunotherapy for cancer.